Drug intelligence / Profile preview

iSCLife I.V. Drip

Development stage: Phase 1
Lead developer: Sclnow Biotechnology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

iSCLife I.V. Drip is an investigational intravenous umbilical cord-derived stem-cell therapy developed by Sclnow Biotechnology. The product is described in the sponsor's pipeline as an iSCLstem-cell product and is being explored across inflammatory and reproductive indications, including Crohn's disease, premature ovarian failure, and uterine scar diverticulum. Its proposed therapeutic rationale is systemic cell-mediated immunoregulation and tissue-repair support; no defined molecular target, engineered-cell phenotype, dose, or clinical phase has been publicly specified.

Brand names: iSCLife I.V. Drip
Other names: iSCLstem cell

Beyond the preview

Go deeper on iSCLife I.V. Drip.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iSCLife I.V. Drip.

Explore the full profile